Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART

Condition:   HIV InfectionsInterventions:   Biological: LC002 standard vaccination;   Biological: LC002 high-dose vaccination;   Biological: LC002 placebo vaccinationSponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   AIDS Clinical Trials GroupCompleted - verified March 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials